Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer

Jason Hongting Leung; Benjamin Ng; Wei-Wen Lim

doi:10.3390/cells11142257

Interleukin-11: A Potential Biomarker and Molecular Therapeutic Target in Non-Small Cell Lung Cancer

Cells. 2022 Jul 21;11(14):2257. doi: 10.3390/cells11142257.

Authors

Jason Hongting Leung¹, Benjamin Ng^{2

3}, Wei-Wen Lim^{2

3}

Affiliations

¹ Department of Cardiothoracic Surgery, National Heart Center Singapore, Singapore 169609, Singapore.
² National Heart Research Institute Singapore, National Heart Center Singapore, Singapore 169609, Singapore.
³ Cardiovascular and Metabolic Disorders Program, Duke-National University of Singapore Medical School, Singapore 169609, Singapore.

Abstract

Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer and is a fast progressive disease when left untreated. Identification of potential biomarkers in NSCLC is an ongoing area of research that aims to detect, diagnose, and prognosticate patients early to optimize treatment. We review the role of interleukin-11 (IL11), a stromal-cell derived pleiotropic cytokine with profibrotic and cellular remodeling properties, as a potential biomarker in NSCLC. This review identifies the need for biomarkers in NSCLC, the potential sources of IL11, and summarizes the available information leveraging upon published literature, publicly available datasets, and online tools. We identify accumulating evidence suggesting IL11 to be a potential biomarker in NSCLC patients. Further in-depth studies into the pathophysiological effects of IL11 on stromal-tumor interaction in NSCLC are warranted and current available literature highlights the potential value of IL11 detection as a diagnostic and prognostic biomarker in NSCLC.

Keywords: biomarkers; cytokines; interleukin-11; non-small cell lung cancer.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Carcinoma, Non-Small-Cell Lung* / pathology
Humans
Interleukin-11 / physiology
Lung Neoplasms* / diagnosis
Lung Neoplasms* / drug therapy
Lung Neoplasms* / pathology

Substances

Biomarkers
Interleukin-11

Grants and funding

J.H.L. is supported by the Ministry of Health Clinician Scientist Residency Seed Fund (MOH-CSSDFD19OCT-0002). B.N. is supported by the National Medical Research Council (NMRC) Open Fund Young Individual Research Grant (NMRC OFYIRG21jun-0022). W.-W.L. is supported by the Advanced Manufacturing and Engineering Young Individual Research Grant (AME YIRG) of Agency for Science, Technology, and Research (A*STAR) award (A2084c0157).